GlassScriptPhysician profile
Taylor Beth Woodson
NPI 1619522414
$2,226.89
in general payments reported to CMS, 2019-2025
28 companies · $998 in 2025
The $998 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.54 · 2023: $218 · 2024: $916 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.75 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $246.43 | 2023-2025 | |
| Lilly USA, LLC | $219.76 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.46 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $97.35 | 2023-2025 | |
| Novo Nordisk INC | $88.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $85.99 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $80.77 | 2023-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $73.02 | 2021-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.81 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $57.87 | 2023-2025 | Veozah |
| Eisai INC. | $49.33 | 2021-2025 | |
| Csl Behring | $47.65 | 2025 | Haegarda |
| Phathom Pharmaceuticals, INC. | $41.09 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $40.58 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.69 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $28.97 | 2024 | Gemtesa |
| Amgen INC. | $28.79 | 2024 | Repatha, Otezla |
| Viatris Specialty LLC | $27.03 | 2025 | Yupelri |
| Mylan Specialty L.P. | $25.77 | 2024 | Yupelri |
| Janssen Biotech, INC. | $22.50 | 2025 | Stelara, Tremfya, Simponi |
| Scilex Pharmaceuticals INC. | $20.92 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.68 | 2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $18.37 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.60 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $16.25 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2025 | |
| Paratek Pharmaceuticals, INC. | $13.18 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Woodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.